As the lights dim in the once-bustling lab spaces across the Greater Boston area, the silence echoes the growing concerns about the future of the biotech industry in the region. High-profile projects, including the former Au Bon Pain headquarters and the $545 million Boston Landing lab facility, sit eerily vacant, casting long shadows over the biotech landscape. Even Ginkgo Bioworks, a stalwart of the biotech community, retreated due to financial constraints, leaving a gaping hole in their newly assigned lab building. This trend, though primarily localized, has implications that resonate across the biotech industry, raising questions about the demand for these specialized spaces and their role in fostering a vibrant biotech ecosystem.
The Boston Planning and Development Agency (BPDA) is preparing to certify the completion of these unoccupied structures. With nearly one million square feet of brand new lab space standing empty, the surplus in lab space has become a pressing issue that needs immediate attention.
It’s a scene reminiscent of a ghost town, but instead of tumbleweeds, there are state-of-the-art lab facilities waiting for the hum of life sciences research to fill their halls. These once sought-after lab spaces, with their high-end amenities and generous square footage, are now forced to confront the reality of a shifting market dynamics for lab co-working spaces.
On the other side of the coin, the biotech industry in the Greater Boston area is not entirely lackluster. Take, for example, the new home of Eli Lilly & Co., a $700 million research and development facility along Fort Point Channel. This lab started construction without a tenant but eventually found its occupant in the pharmaceutical giant, which leased the whole facility and moved in last year. Other bright spots include the labs under construction for AstraZeneca and Takeda in Kendall Square.
However, these glimmers of hope are overshadowed by the daunting statistic that nearly one-third of lab space across the region is available for lease. This, along with the 3 to 4 million square feet of space currently under construction, threatens to oversaturate the market, potentially leading to a 5% growth in the market size, according to research from Newmark and Colliers.
The surplus of vacant lab space is a ticking time bomb for landlords who are burdened with loans that they might struggle to repay. “This vacancy is going to linger,” warns Jeff Myers, research director at real estate firm Colliers, implying potential rock-bottom sales in the future.
The current landscape of the Greater Boston area serves as an alarm bell for the biotech industry, signaling a need for a comprehensive reassessment of lab space utilization and market strategies. By understanding the reasons behind this surplus, stakeholders can devise effective strategies to attract tenants to these specialized spaces, repurpose them, or prevent such a surplus in the future. This is a crucial step in preserving the vitality of the biotech ecosystem in Greater Boston and beyond.
Read more from boston.com
